Insider Trading Alert - DXCM, FDP And OCRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 6, 2015, 74 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.44 to $8,899,995.42.

Highlighted Stocks Traded by Insiders:

DexCom (DXCM) - FREE Research Report

Sayer Kevin R, who is President & CEO at DexCom, sold 25,000 shares at $68.01 on May 6, 2015. Following this transaction, the President & CEO owned 407,360 shares meaning that the stake was reduced by 5.78% with the 25,000-share transaction.

The shares most recently traded at $67.12, down $0.89, or 1.33% since the insider transaction. Historical insider transactions for DexCom go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 27,698
  • 24-Week # shares sold: 39,698

The average volume for DexCom has been 717,600 shares per day over the past 30 days. DexCom has a market cap of $5.2 billion and is part of the health care sector and health services industry. Shares are up 20.25% year-to-date as of the close of trading on Wednesday.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. Currently, there are 9 analysts who rate DexCom a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DXCM - FREE

TheStreet Quant Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Apple Watch Is on Its Way to Becoming a $6 Billion Business, but Is That Really Enough?

DexCom Shares Rise After FDA Approves G5 Mobile App for Android Devices

Apple Watch Appears on Its Way to Becoming a $6 Billion Business

DexCom Stock Surging on Apple Watch Partnership

Markets Down? Get Used to It: Cramer's 'Mad Money' Recap (Wednesday 5/17/17)